Health Care • Biotechnology: Pharmaceutical Preparations
$30.22 ▲ +0.11
(+0.37%)
MKT CAP: $1.38B • VOL: 139.0K
52W L $7 52W H $59
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$25
MEDIAN
$34
MEAN
$34
HIGH
$41
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KRSA TAPE
KRSA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $36.57 | $34.75 | 2025-02-14 | $27.50 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $38.08 | $35.66 | 2025-02-06 | $28.41 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $34.45 | $33.24 | 2025-01-29 | $29.01 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $30.82 | — | 2025-01-17 | $29.62 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $26.59 | $28.71 | 2025-01-09 | $26.90 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $35.96 | $31.43 | 2024-12-18 | $26.29 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $29.31 | $30.52 | 2024-12-04 | $28.10 | -4.3% | 48% | C |